FDA recall, , Low risk
Trokendi XR (Topiramate) Extended-Release Capsules
Trokendi XR extended-release capsules failed dissolution specifications.
Summary by Recall Canary from the FDA notice
What happened
Supernus Pharmaceuticals, Inc., of Rockville, Maryland, recalled Trokendi XR (topiramate) extended-release capsules, 50 mg, 30 capsules, because the product failed dissolution specifications. The recall began August 31, 2026, and was added to the FDA's Enforcement Report on September 3, 2026. The product was distributed nationwide in the United States.
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:
- Check the FDA or company notice for instructions specific to this product.
- Ask your pharmacist or doctor whether your lot is affected and what to do.
Is yours affected?
Match the NDC and lot code listed under your product.
An NDC (National Drug Code) is usually printed on the drug's label.
Trokendi XR (topiramate) extended-release capsules
- NDC
- 17772-102-30
- Lot code
- 2145283
- 31-Mar-2030
Recall details
- Company began the recall
- Sold in
US Nationwide.
- Company
- Supernus Pharmaceuticals, Inc.Rockville, Maryland
- Hazard
- Drug dissolving problem
- Risk
Low risk
Taking it is unlikely to cause health problems.
FDA Class III recall · How risk is rated
- Event ID
- 99767
- Recall number
- D-0833-2026
- Quantity recalled
- 11304 bottles
All recalls from Supernus Pharmaceuticals, Inc.
Timeline
FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.
Company began the recall
Added to FDA's Enforcement Report · Classified by FDA
Listed on Recall Canary
In FDA's weekly enforcement report
Summary updated
